Zevalin

Zevalin (ibritumomab tiuxetan) is an intravenous radioimmunotherapy medication used for certain types of non-Hodgkin lymphoma. This targeted therapy combines a monoclonal antibody with a radioactive isotope to treat cancer. Always consult a healthcare provider for personalized guidance.

Zevalin is primarily used to treat non-Hodgkin lymphoma, a type of cancer affecting the lymphatic system. It is indicated for patients with relapsed or refractory low-grade, follicular, or transformed B-cell lymphomas. The therapy targets CD20-positive B-cells, helping to reduce cancerous cells in the body. Patients often ask, 'what is Zevalin used for' when exploring treatment options.

Zevalin works by delivering radiation directly to cancerous B-cells while sparing healthy tissues. Patients may experience effects such as fatigue, nausea, or low blood cell counts as the body responds to treatment. These effects vary depending on individual health conditions and treatment protocols. Monitoring by a healthcare provider is essential during therapy.

Zevalin should only be administered under the supervision of a qualified healthcare professional in a controlled medical setting. Patients must undergo thorough screening to ensure suitability for radioimmunotherapy. Hydration and infection prevention measures may be recommended before and after treatment. Always disclose your full medical history to your provider.

Zevalin may interact with other medications affecting the immune system or blood cell counts, such as immunosuppressants or chemotherapy drugs. Live vaccines should be avoided during and after treatment due to potential risks. Patients should inform their healthcare provider about all medications, including over-the-counter and herbal supplements. Alcohol use may exacerbate certain side effects.